Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

20/11/2015 - 2 minutes

This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is also the residence for our biotech of the week: Opsona Therapeutics


City: Dublin, Ireland

Founded: 2004

Financial Data: €51.7M total raised (as of 02/15)

Employees: 19 (02/15)


Mission: Opsona Therapeutics is currently at the forefront of drug development in immunology research, with the focus being on the modulation of the human innate immune system. Opsona is primarily looking into tackling the pathways that initiate the innate immune system, such as Toll-Like Receptors (TLRs) and the inflammasome. They currently have one product in the pipeline, OPN-305, a TLR-specific monoclonal antibody and pre-clinical data indicates it is a potent inhibitor of TLR mediated pro-inflammatory cytokine production.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member